April 22, 2024

5-Day Course: Gene Therapy Innovations – from science and manufacturing to patient benefit

5-Day Course: Gene Therapy Innovations – from science and manufacturing to patient benefit

EATRIS is hosting a 5-day course “Gene Therapy Innovations” from bench to patient in Belgium from 18-22 November together with the GET-IN project. PhD students and early PostDocs will learn from real-life scenarios presented by experts and group assignments. The course will address key aspects for successfully translating research into patient benefit like Manufacturing, Regulatory, Clinical aspects, Commercialisation and Reimbursement. Please help us to reach out to the excellent potential participants in your network (see announcement text to share via email below).

There is a 100€ discount for EATRIS members and an additional discount for participants from EU-13 countries.

For additional information or any feedback, please reach out to the training team (training@eatris.eu)

GENE THERAPY INNOVATIONS – FROM SCIENCE AND MANUFACTURING TO PATIENT BENEFIT

Date & Time 18-22 November 2024
Address KU Leuven 01.10 – Nicolas de le Villezaal – Celestijnenklooster – CBA (331-80) Willem de Croylaan 6 , 3001 Heverlee
Sciencepark Arenberg, Bio-Incubator Leuven NV, Gaston Geenslaan 3, 3001 Heverlee
UCB Pharma, Avenue de l’Industrie B – 1420 Braine-l’Alleud
Location Leuven, Belgium

JOIN US FOR THIS 5-DAY COURSE ON “GENE THERAPY INNOVATIONS” ON 18-22 NOVEMBER 2024 IN LEUVEN, BELGIUM.

The agenda of the course will address the 4 key challenges and bottlenecks of the gene therapy development cycle: Scientific, Manufacturing, Regulatory, and Reimbursement/Commercialisation. In addition, clinical aspects will be discussed.

The course is developed and proposed within the scope of the GET-IN doctoral network tackling critical gene therapy technology & knowledge gaps. It will be building on the knowledge of the online course and face-to-face curriculum on ATMPs (Cell and Gene Therapies) development that was developed within the ADVANCE project (2020-2023).

The core target group are the “next generation of gene therapy developers” – i.e. early-career biomedical academics (PhDs, Postdocs), including doctors in training, clinician-scientists and SME-based professionals, who are considered to be an important component of the labour market and the critical intermediaries of the gene therapy development pipeline.

Participants will:

  • Take a preparatory online course
  • hear keynote lectures by experts,
  • complete hands-on group assignments,
  • get a chance to present their research projects to peers,
  • go on tours of gene therapies production facilities (Leuven BioIncubator, UCB)
  • have plenty of time to network with peers!

Lecturers: Andrea Buzzi (European Medicines Agency), Rik Gijsberg (KU Leuven), David Morrow (EATRIS), Jan Schrooten (Antleron), Laetitia Malphettes (UCB), Liesbeth De Waele (UZ Leuven), Isabelle Huys (KU Leuven), …

TIME AND LOCATION

Start: 9.00 on 18 November

End: 12.00 on 22 November

 

APPLICATION

30 seats are available, first come first serve, and we recommend to register early!

Registration fee includes daytime catering (lunch and refreshments) plus 1 evening social activity.  Travel and accommodation are not included.

  • For GET-IN DCs, GET-IN members and EATRIS members: 550€
  • For participants from academia: 650€
  • For participants from industry: 850€
  • 2 seats at 350€ are reserved for participants from EU-13 countries: Bulgaria (BG), Croatia (HR), Cyprus (CY), Czech Republic (CZ), Estonia (EE), Hungary (HU), Latvia (LV), Lithuania (LT), Malta (MT), Poland (PL), Romania (RO), Slovakia (SK) and Slovenia (SI)

Registration Link

register now

Our latest News

discover more
TRANSVAC: a pillar of vaccine development in Europe for 16 years

TRANSVAC: a pillar of vaccine development in Europe for 16 years

The European vaccine development ecosystem has been strengthened over the last 16 years, thanks to the EVI-led TRANSVAC project, an ambitious initiative funded by the European Commission. Since its launch in 2009, TRANSVAC has established itself as a key player in advancing vaccine research, supporting over 160 vaccine projects while fostering innovation and collaboration in […]

Novel analysis of intrinsically disordered proteins

Novel analysis of intrinsically disordered proteins

Researchers from Mainz University and EMBL Hamburg present a new approach for structurally characterising disordered proteins by combining two different analysis methods. Proteins are the molecules that perform most ‘actions’ in the cell, and thus, are key for our body functions. Essentially, proteins are strings of amino acids, which, in most cases, fold like origami […]

Repeated polyp diagnoses in relatives indicate higher risk of colorectal cancer

Repeated polyp diagnoses in relatives indicate higher risk of colorectal cancer

Researchers at the German Cancer Research Center (DKFZ) and at the National Center for Tumor Diseases (NCT) Heidelberg have investigated the association between an individual’s risk of colorectal cancer and repeated diagnoses of colorectal polyp in relatives. They conclude that, in particular, the risk of developing colorectal cancer at a young age is significantly increased […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp